KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $34.2 million.

  • Vir Biotechnology's Other Non-Current Liabilities rose 304.49% to $34.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.2 million, marking a year-over-year increase of 304.49%. This contributed to the annual value of $24.0 million for FY2024, which is 735.75% down from last year.
  • Vir Biotechnology's Other Non-Current Liabilities amounted to $34.2 million in Q3 2025, which was up 304.49% from $33.6 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Other Non-Current Liabilities high stood at $46.0 million for Q1 2021, and its period low was $18.9 million during Q1 2022.
  • Over the past 5 years, Vir Biotechnology's median Other Non-Current Liabilities value was $26.0 million (recorded in 2023), while the average stood at $28.5 million.
  • In the last 5 years, Vir Biotechnology's Other Non-Current Liabilities soared by 22777.5% in 2021 and then plummeted by 5896.47% in 2022.
  • Quarter analysis of 5 years shows Vir Biotechnology's Other Non-Current Liabilities stood at $22.8 million in 2021, then rose by 9.27% to $24.9 million in 2022, then rose by 4.1% to $26.0 million in 2023, then dropped by 7.36% to $24.0 million in 2024, then soared by 42.12% to $34.2 million in 2025.
  • Its Other Non-Current Liabilities stands at $34.2 million for Q3 2025, versus $33.6 million for Q2 2025 and $23.6 million for Q1 2025.